Logo image of DCTH

DELCATH SYSTEMS INC (DCTH) Stock Overview

NASDAQ:DCTH - US24661P8077 - Common Stock

10.9 USD
-0.12 (-1.09%)
Last: 9/2/2025, 8:00:01 PM
10.96 USD
+0.06 (+0.55%)
After Hours: 9/2/2025, 8:00:01 PM

DCTH Key Statistics, Chart & Performance

Key Statistics
52 Week High18.23
52 Week Low8.08
Market Cap381.28M
Shares34.98M
Float34.03M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.05
PE218
Fwd PE22.33
Earnings (Next)11-06 2025-11-06/amc
IPO10-19 2000-10-19
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


DCTH short term performance overview.The bars show the price performance of DCTH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

DCTH long term performance overview.The bars show the price performance of DCTH in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of DCTH is 10.9 USD. In the past month the price decreased by -3.28%. In the past year, price increased by 12.72%.

DELCATH SYSTEMS INC / DCTH Daily stock chart

DCTH Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 26.83 228.80B
ISRG INTUITIVE SURGICAL INC 58.27 168.15B
BSX BOSTON SCIENTIFIC CORP 37.69 158.04B
SYK STRYKER CORP 30.35 149.08B
MDT MEDTRONIC PLC 16.88 119.71B
BDX BECTON DICKINSON AND CO 13.19 53.93B
IDXX IDEXX LABORATORIES INC 53.24 51.16B
EW EDWARDS LIFESCIENCES CORP 31.82 48.01B
RMD RESMED INC 28.38 39.68B
GEHC GE HEALTHCARE TECHNOLOGY 15.36 32.69B
DXCM DEXCOM INC 43.71 29.14B
PHG KONINKLIJKE PHILIPS NVR- NY 16.11 26.06B

About DCTH

Company Profile

DCTH logo image Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. The company is headquartered in Queensbury, New York and currently employs 96 full-time employees. The company went IPO on 2000-10-19. The firm's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Company Info

DELCATH SYSTEMS INC

566 Queensbury Avenue

Queensbury NEW YORK 10019 US

CEO: Gerard Michel

Employees: 96

DCTH Company Website

DCTH Investor Relations

Phone: 15187438892

DELCATH SYSTEMS INC / DCTH FAQ

What is the stock price of DELCATH SYSTEMS INC today?

The current stock price of DCTH is 10.9 USD. The price decreased by -1.09% in the last trading session.


What is the ticker symbol for DELCATH SYSTEMS INC stock?

The exchange symbol of DELCATH SYSTEMS INC is DCTH and it is listed on the Nasdaq exchange.


On which exchange is DCTH stock listed?

DCTH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for DELCATH SYSTEMS INC stock?

12 analysts have analysed DCTH and the average price target is 25.21 USD. This implies a price increase of 131.27% is expected in the next year compared to the current price of 10.9. Check the DELCATH SYSTEMS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is DELCATH SYSTEMS INC worth?

DELCATH SYSTEMS INC (DCTH) has a market capitalization of 381.28M USD. This makes DCTH a Small Cap stock.


How many employees does DELCATH SYSTEMS INC have?

DELCATH SYSTEMS INC (DCTH) currently has 96 employees.


What are the support and resistance levels for DELCATH SYSTEMS INC (DCTH) stock?

DELCATH SYSTEMS INC (DCTH) has a support level at 10.82 and a resistance level at 10.99. Check the full technical report for a detailed analysis of DCTH support and resistance levels.


Is DELCATH SYSTEMS INC (DCTH) expected to grow?

The Revenue of DELCATH SYSTEMS INC (DCTH) is expected to grow by 163.5% in the next year. Check the estimates tab for more information on the DCTH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy DELCATH SYSTEMS INC (DCTH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does DELCATH SYSTEMS INC (DCTH) stock pay dividends?

DCTH does not pay a dividend.


When does DELCATH SYSTEMS INC (DCTH) report earnings?

DELCATH SYSTEMS INC (DCTH) will report earnings on 2025-11-06, after the market close.


What is the Price/Earnings (PE) ratio of DELCATH SYSTEMS INC (DCTH)?

The PE ratio for DELCATH SYSTEMS INC (DCTH) is 218. This is based on the reported non-GAAP earnings per share of 0.05 and the current share price of 10.9 USD. Check the full fundamental report for a full analysis of the valuation metrics for DCTH.


What is the Short Interest ratio of DELCATH SYSTEMS INC (DCTH) stock?

The outstanding short interest for DELCATH SYSTEMS INC (DCTH) is 8.9% of its float. Check the ownership tab for more information on the DCTH short interest.


DCTH Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

DCTH Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to DCTH. DCTH has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DCTH Financial Highlights

Over the last trailing twelve months DCTH reported a non-GAAP Earnings per Share(EPS) of 0.05. The EPS increased by 101.96% compared to the year before.


Industry RankSector Rank
PM (TTM) 3.18%
ROA 1.91%
ROE 2.13%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%114.58%
Sales Q2Q%211.05%
EPS 1Y (TTM)101.96%
Revenue 1Y (TTM)491.54%

DCTH Forecast & Estimates

12 analysts have analysed DCTH and the average price target is 25.21 USD. This implies a price increase of 131.27% is expected in the next year compared to the current price of 10.9.

For the next year, analysts expect an EPS growth of 99.11% and a revenue growth 163.5% for DCTH


Analysts
Analysts85
Price Target25.21 (131.28%)
EPS Next Y99.11%
Revenue Next Year163.5%

DCTH Ownership

Ownership
Inst Owners43.89%
Ins Owners2.73%
Short Float %8.9%
Short Ratio3.64